Growth Metrics

Opus Genetics (IRD) Research & Development (2010 - 2026)

Opus Genetics (IRD) reported Research & Development of $10.6 million for Q1 2026, up 32.99% year-over-year from $8.0 million in Q1 2025, and up 1.43% on a QoQ basis from $10.4 million in Q4 2025.

Opus Genetics (IRD) has 17 years of Research & Development data on file, last reported at $10.6 million in Q1 2026.

  • Quarterly Research & Development rose 32.99% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.4 million (up 11.25% YoY) and the FY2025 annual result came in at $30.8 million, up 14.75% from the prior year.
  • Research & Development grew to $10.6 million in Q1 2026 per IRD's latest filing, from $10.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.6 million in Q1 2026 and bottomed at $2.8 million in Q3 2022.
  • The 5-year median for Research & Development is $5.6 million (2023), against an average of $5.9 million.
  • The widest annual swing landed in 2024, when Research & Development jumped 157.07%; it then fell 28.65% in 2025.
  • Tracing IRD's Research & Development over 5 years: stood at $3.6 million in 2022, then advanced by 7.11% to $3.8 million in 2023, then soared by 83.13% to $7.0 million in 2024, then surged by 48.25% to $10.4 million in 2025, then climbed by 1.43% to $10.6 million in 2026.
  • Per Business Quant, the three latest IRD Research & Development figures stand at $10.6 million (Q1 2026), $10.4 million (Q4 2025), and $6.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 626,092.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 4.32 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -101.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 1.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 961.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -2.30 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.54 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 364.87 Mn
10 Opus Genetics 357.99 Mn 298.03 Mn - 10.58 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 10.58 Mn
Dec 31, 2025 10.43 Mn
Sep 30, 2025 6.41 Mn
Jun 30, 2025 6.02 Mn
Mar 31, 2025 7.95 Mn
Dec 31, 2024 7.03 Mn
Sep 30, 2024 8.98 Mn
Jun 30, 2024 6.09 Mn
Mar 31, 2024 4.75 Mn
Dec 31, 2023 3.84 Mn
Sep 30, 2023 3.49 Mn
Jun 30, 2023 4.72 Mn
Mar 31, 2023 5.60 Mn
Dec 31, 2022 3.59 Mn
Sep 30, 2022 2.84 Mn
Jun 30, 2022 3.16 Mn
Mar 31, 2022 4.77 Mn
Dec 31, 2021 4.74 Mn
Sep 30, 2021 3.13 Mn
Jun 30, 2021 3.83 Mn
Mar 31, 2021 3.48 Mn
Dec 31, 2020 4.34 Mn
Sep 30, 2020 1.38 Mn
Jun 30, 2020 711,000.00
Mar 31, 2020 218,000.00
Dec 31, 2019 -2.65 Mn
Sep 30, 2019 1.13 Mn
Jun 30, 2019 1.65 Mn
Mar 31, 2019 2.24 Mn
Dec 31, 2018 2.73 Mn
Sep 30, 2018 2.89 Mn
Jun 30, 2018 3.43 Mn
Mar 31, 2018 4.06 Mn
Dec 31, 2017 3.26 Mn
Sep 30, 2017 2.64 Mn
Jun 30, 2017 2.54 Mn
Mar 31, 2017 2.26 Mn
Dec 31, 2016 2.08 Mn
Sep 30, 2016 2.30 Mn
Jun 30, 2016 2.24 Mn
Mar 31, 2016 3.47 Mn
Dec 31, 2015 2.92 Mn
Sep 30, 2015 3.10 Mn
Jun 30, 2015 3.24 Mn
Mar 31, 2015 2.89 Mn
Dec 31, 2014 2.22 Mn
Sep 30, 2014 1.82 Mn
Jun 30, 2014 1.70 Mn
Mar 31, 2014 1.27 Mn
Dec 31, 2013 994,262.00
Sep 30, 2013 781,281.00
Jun 30, 2013 925,130.00
Mar 31, 2013 552,466.00
Dec 31, 2012 265,695.00
Sep 30, 2012 1.07 Mn
Jun 30, 2012 1.02 Mn
Mar 31, 2012 1.04 Mn
Dec 31, 2011 1.49 Mn
Sep 30, 2011 2.37 Mn
Jun 30, 2011 5.42 Mn
Mar 31, 2011 2.72 Mn
Dec 31, 2010 1.48 Mn
Sep 30, 2010 671,339.00
Jun 30, 2010 1.33 Mn